IP Library Patent Application 18943440
Patent Application
App. No. 18/943,440

PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/943,440
Abstract

Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.

Claims (8)

1 - 79 . (canceled)

80 . A peptide product comprising: His 1 -Aib 2 -Gln 3 -Gly 4 -Thr 5 -Phe 6 -Thr 7 -Ser 8 -Asp 9 -Tyr 10 -Ser 11 -Lys 12 -Tyr 13 -Leu 14 -Asp 15 -Glu* 16 -Lys(N-omega(1-(17-carboxyl-heptadecyloxy) beta-D-glucuronyl)) 17 -Ala 18 -Ala 19 -Lys* 20 -Glu 21 -Phe 22 -Ile 23 -Gln 24 -Trp 25 -Leu 26 -Leu 27 -Gln 28 -Thr 29 -NH 2 (SEQ. ID. NO. 1119) or a pharmaceutically acceptable salt thereof.

81 . A pharmaceutical composition comprising a peptide product having formula His 1 -Aib 2 -Gln 3 -Gly 4 -Thr 5 -Phe 6 -Thr 7 -Ser 8 -Asp 9 -Tyr 10 -Ser 11 -Lys 12 -Tyr 13 -Leu 14 -Asp 15 -Glu* 16 -Lys(N-omega(1-(17-carboxyl-heptadecyloxy) beta-D-glucuronyl)) 17 -Ala 18 -Ala 19 -Lys* 20 -Glu 21 -Phe 22 -Ile 23 -Gln 24 -Trp 25 -Leu 26 -Leu 27 -Gln 28 -Thr 29 -NH 2 (SEQ. ID. NO. 1119) or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier or excipient.

82 . A method of producing a peptide product comprising formula His 1 -Aib 2 -Gln 3 -Gly 4 -Thr 5 -Phe 6 -Thr 7 -Ser 8 -Asp 9 -Tyr 10 -Ser 11 -Lys 12 -Tyr 13 -Leu 14 -Asp 15 -Glu* 16 -Lys(N-omega(1-(17-carboxyl-heptadecyloxy) beta-D-glucuronyl)) 17 -Ala 18 -Ala 19 -Lys* 20 -Glu 21 -Phe 22 -Ile 23 -Gln 24 -Trp 25 -Leu 26 -Leu 27 -Gln 28 -Thr 29 -NH 2 (SEQ. ID. NO. 1119) or a pharmaceutically acceptable salt thereof, comprising:

conjugating a surfactant intermediate to a protected peptide intermediate; and

deprotecting the peptide.

83 . The method claim 82 , wherein the surfactant intermediate is protected, and the method further comprises deprotecting the surfactant after conjugation of the protected surfactant intermediate to the protected peptide intermediate.

84 . The method claim 82 , further comprising removing the peptide-surfactant conjugate from a solid support.

Assignments (4)
SECURITY INTEREST Recorded May 14, 2025
From: ALTIMMUNE, INC.; SPITFIRE PHARMA, LLC
To: HERCULES CAPITAL, INC., AS AGENT
Reel/Frame 071108/0692 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2025
From: N, JOHN J.
To: SPITFIRE PHARMA, INC.
Reel/Frame 070262/0605 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2025
From: SPIRFIRE PHARMA, INC.
To: MEDERIS DIABETES LLC
Reel/Frame 070262/0648 →
AFFIDAVIT OF ADDRESS CHANGE Recorded Feb 19, 2025
From: MEDERIS DIABETES, LLC
To: MEDERIS DIABETES LLC
Reel/Frame 070266/0875 →